Skip to main content
APhA DrugInfoLine
Sign in to your APhA membership account
Download a PDF of this month's content | Download a PDF of last month's content |Advanced Search
  • HOME
  • NEURO/PSYCH
    • Neurology
    • Psychiatry
  • HEART/LUNGS
    • Cardiology
    • Focus on Lipids Care
    • Focus on Anticoagulation Care
    • Respiratory
    • Focus on Asthma Care
  • GI/KIDNEYS
    • Gastroenterology
    • Nephrology
  • ENDOCRINE/RHEUM
    • Endocrinology
    • Focus on Diabetes Care
    • Rheumatology
  • ID/CANCERS
    • Infectious Diseases
    • Focus on HIV Care
    • Focus on Immunizations
    • Oncology
  • SELF-CARE
    • Alternative Medicines Corner
    • OTC Medicines Corner
  • PERSONALIZED CARE
    • Drug Interactions Corner
    • Pharmacogenomics Corner
  • Heart/Lungs
    Cardiology...
    April 24, 2018

    Safety concerns with digoxin use

    READ
  • GI/Kidneys
    Nephrology...
    April 24, 2018

    Trimethoprim is associated with negative renal outcomes in older adults

    READ
  • Neuro/Psych
    Psychiatry...
    April 16, 2018

    New analysis compares the efficacy and safety of antidepressants

    READ
  • ID/Cancers
    Infectious Diseases...
    April 16, 2018

    Updated Clostridium difficile guidelines released

    READ
  • GI/Kidneys
    Nephrology...
    April 10, 2018

    No renal benefits with sodium bicarbonate or acetylcysteine...

    READ
  • Heart/Lungs
    Focus on Anticoagulat...
    April 10, 2018

    New oral option for cancer-associated VTE

    READ
  • ID/Cancers
    Focus on HIV Care...
    April 2, 2018

    Two-drug regimens might be as effective as three-drug regimens...

    READ
  • Heart/Lungs
    Cardiology...
    April 2, 2018

    Intensive BP control beneficial in patients with type 2 diabetes...

    READ
  • Heart/Lungs
    Respiratory...
    March 27, 2018

    Combination therapy for pulmonary fibrosis may be an option

    READ
  • ID/Cancers
    Oncology...
    March 27, 2018

    CAR T-cell therapy effective, but serious toxicities and high...

    READ
  • Self-care
    Alternative Medicines C...
    March 20, 2018

    Omega-3 fatty acid supplementation and CV benefits

    READ
  • Read more about New HIV treatment approved for patients with limited treatment options
  • Read more about Surgical site infection risk increased in patients who reported a penicillin allergy
  • Read more about Herb–drug interactions can result in serious adverse drug reactions
  • Read more about FDA warns not to use compounded drugs from Cantrell Drug Co.
  • Read more about Agent plus prednisone approved for treatment of earlier form of metastatic prostate cancer
  • Read more about Agent approved as initial therapy for HR-positive, HER2-negative metastatic breast cancer
  • Read more about FDA approves benzhydrocodone/acetaminophen for short-term management of acute pain
  • Read more about Potential increased risk of heart problems or death in patients with heart disease
  • Read more about New ER formulation for treatment of Parkinson disease, drug-induced involuntary movements in adults
  • Read more about FDA expands approval to reduce the risk of NSCLC progressing

Medication Monitor

NEW DRUG APPROVALS

  • April 18, 2018
    Fostamatinib disodium hexahydrate
    (Tavalisse):
    New drug targets chronic immune thrombocytopenia in adults
  • April 17, 2018
    Burosumab
    (Crysvita):
    FDA approves first therapy for rare inherited form of rickets, x-linked hypophosphatemia
See more New Drug Approvals

SUPPLEMENTAL APPROVALS

  • April 19, 2018
    Idarucizumab
    (Praxbind):
    Idarucizumab approved as first reversal agent for novel oral anticoagulant dabigatran
  • April 16, 2018
    Nivolumab and ipilimumab
    (Opdivo and Yervoy):
    FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma
See more Supplemental Approvals

ALERTS AND RECALLS

  • April 17, 2018
    Highly concentrated caffeine
    (Multiple trade names):
    FDA warns of dangers of extremely concentrated or pure caffeine sold in bulk
See more Alerts and Recalls

PRODUCT WITHDRAWALS

  • March 26, 2018
    Daclizumab
    (Zinbryta):
    Daclizumab withdrawn after reports of serious inflammatory brain disorders
See more Product withdrawals


                                

Editor's Picks

  • Safety concerns with digoxin use
  • Trimethoprim is associated with negative renal...
  • New analysis compares the efficacy and safety of...
  • Updated Clostridium difficile guidelines released
  • No renal benefits with sodium bicarbonate or...

Popular Articles

  • Updated diabetes standards released by the...
  • Updated blood pressure guideline released
  • Choice of bowel preparation for colonoscopy...
  • Testosterone replacement resulting in more harm...
  • Unique dosing regimen may result in better iron...

Popular Sections

  • Alerts and Recalls
  • Supplemental Approvals
  • New Drug Approvals
  • Cardiology
  • Alternative Medicines Corner

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

More info

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.

  • Contact Us
  • Section Advisors
  • Terms of Use
  • Privacy Policy